IL1B and atherosclerosis: Furthermore, we demonstrated that pharmacological interventions targeting the UCP1/MMP/NLRP3 inflammasome–IL-1β axis are promising therapeutic strategies for the treatment of atherosclerosis in small- and large-animal models.